Enzon Pharmaceuticals Surges Post-Klarman Sale

Enzon Pharmaceuticals Surges Post-Klarman Sale

Today’s midday gainers are Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Gilead Sciences, Inc. (NASDAQ:GILD) and Sirius XM Holdings Inc. (NASDAQ:SIRI). J.C. Penney Company, Inc. (NYSE:JCP), MakeMyTrip Limited (NASDAQ:MMYT) and Kindred Biosciences Inc (NASDAQ:KIN) are the losers.

Enzon Pharmaceuticals Surges

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) surged +4.77% midday today, rendering it this Friday’s top midday gainer. The Carl Icahn holding used to be also part of Seth Klarman’s portfolio, but it was announced yesterday that he was closing his position in the biotech company.

Khrom Capital killed it during the first quarter, continuing its strong track record; here are their favorite stocks

Khrom Capital was up 32.5% gross and 24.5% net for the first quarter, outperforming the Russell 2000's 21.2% gain and the S&P 500's 6.2% increase. The fund has an annualized return of 21.6% gross and 16.5% net since inception. The total gross return since inception is 1,194%. Q1 2021 hedge fund letters, conferences and more Read More

Gilead Sciences, Inc. (NASDAQ:GILD) rebounded +4.34% after a steep fall yesterday. The firm announced new data on drug studies, which will likely help its product offering in the long-run. Tiger Global, Daniel Loeb and Ray Dalio have positions in Gilead.

And on the heels of good news about its senior notes, Sirius XM Holdings is up +4.19%. The satellite radio company is part of Leon Cooperman’s fund.

J.C. Penney is Back in the Red

After performing quite well over the past month, J.C. Penney Company, Inc. (NYSE:JCP) took a dive, its price falling -8.33%. JCP shares have failed to break resistances some time now. The retailer is a George Soros pick.

Tiger Global bet MakeMyTrip Limited (NASDAQ:MMYT), an online provider of travel services in India, posting a -6.09% decline this Friday. The stock is still up +23.36% YTD.

Klarman biotech stock Kindred Biosciences Inc (NASDAQ:KIN) fell -4.69%. This is the second consecutive day the company makes our list of losers – the result of analyst downgrades. Farallon Capital Management has a position in Kindred.

No posts to display